New MiniPromoter Ple389 (ADORA2A) Drives Selective Expression in Medium Spiny Neurons in Mice and Non-human Primates

A. Gomes, Terri L. Petkau, Andrea J. Korecki, Oriol Fornés, Adriana Galván, Ge Lu, Austin M. Hill, Siu Ling Lam, Andrew Chi-Chih Yao, Rachelle A. Farkas, Wyeth W. Wasserman, Yoland Smith, Elizabeth M. Simpson, Blair R. Leavitt

TL;DR

Researchers have engineered a compact DNA "MiniPromoter" called Ple389 that selectively drives gene expression in D2-type medium spiny neurons within the striatum. Validated in both mice and non-human primates, this tool overcomes the strict size limits of viral vectors, providing a high-precision delivery mechanism for treating neurodegenerative disorders like Huntington’s and Parkinson’s disease.

What Problem Does This Paper Address?

Gene therapy holds immense promise for treating brain disorders, but it faces a "packaging" problem. The gold-standard delivery vehicle, recombinant adeno-associated virus (rAAV), has a tiny cargo capacity of only ~4.9 kb. Standard human promoters—the "on switches" for genes—are often too large to fit alongside the therapeutic payload.

Furthermore, the brain is incredibly complex. To treat diseases like Huntington’s, we need to target specific cells, such as Medium Spiny Neurons (MSNs) in the striatum, without affecting the rest of the brain or body. Existing promoters often "leak," expressing genes in the wrong regions or cell types, which can lead to side effects. This paper seeks to design "MiniPromoters" that are both small enough to fit in an AAV and precise enough to target specific MSN subtypes.

Methods

The authors utilized a combination of bioinformatics and in vivo testing:

  • Design: They developed 12 human-DNA MiniPromoters derived from eight genes known to be active in MSNs. Designs were created either manually or using OnTarget, a webserver that identifies critical cis-regulatory regions (CRRs) like enhancers and promoters.
  • Viral Vector: The promoters were packaged into rAAV-PHP.B, a specialized viral capsid capable of crossing the blood-brain barrier with high efficiency.
  • Testing Pipeline: They tested the designs across three increasingly complex systems:
  • Intravenous (IV) injection in mice to assess systemic spread and CNS entry.
  • Intracerebroventricular (ICV) injection in mice to look at direct brain distribution.
  • ICV injection in non-human primates (rhesus macaques) to ensure the results translate to higher-order brains.
  • Validation: They used RNA in situ hybridization and immunohistochemistry to count exactly which cells were "turning on" the reporter gene (EmGFP).

Datasets

The study relied on several foundational genomic datasets to design the promoters:

  • UCSC Genome Browser: For identifying conserved DNA sequences.
  • ENCODE & FANTOM5: For mapping enhancers and transcription factor binding sites.
  • ATAC-seq & CAGE: Specifically, they used ATAC-seq data from post-mortem human brain tissue (accumbens and putamen) to identify regions of "open" chromatin where regulatory elements reside.
  • Allen Mouse Brain Atlas: Used as the anatomical reference for identifying brain regions during evaluation.

Key Insights and Ideas

  • The Power of Ple389: Derived from the ADORA2A gene, Ple389 emerged as the "Goldilocks" promoter. It is compact (1,344 bp) and highly specific to D2-type MSNs, which are the cells most vulnerable in the early stages of Huntington’s disease.
  • Bioinformatics vs. Manual Design: The study highlighted that automated refinement matters. An earlier manual design for the same gene (Ple355) was much larger and less specific than the OnTarget-refined Ple389.
  • Cross-Species Success: One of the biggest hurdles in neuroscience is the "mouse-to-man" gap. Ple389 maintained its striatal preference in rhesus macaques, suggesting the regulatory logic it uses is evolutionarily conserved.
  • The GPR6 Surprise: Ple385 (derived from GPR6) was expected to target D2 neurons but actually showed a preference for D1 neurons in mice. This highlights that isolated "Mini" versions of promoters can sometimes behave differently than their full-length genomic counterparts.

Key Results

  • Ple389 Specificity: In mice, 86.67% of cells expressing the Ple389-driven gene were confirmed D2-type MSNs.
  • Striatal Enrichment: When delivered via IV in mice, Ple389 showed almost no expression in the cortex or thalamus, effectively "ignoring" most of the brain to focus on the striatum.
  • Primate Validation: In the rhesus macaque, Ple389 drove robust expression in the caudate nucleus (part of the striatum), with clear axonal projections to the globus pallidus and substantia nigra—the exact circuitry involved in motor control.
  • Size Efficiency: The promoters ranged from a tiny 516 bp to ~2.6 kb, all well within the limits for AAV packaging.

Limitations and Future Work

  • NHP Sample Size: The primate data came from a single successful animal (a second animal failed to show transduction for unknown reasons), which is common in pilot NHP studies but requires further scaling.
  • Off-target Peripheral Expression: While specific within the brain, IV delivery still led to some expression in the liver. Future work may need to combine these promoters with "microRNA targets" to actively suppress expression in peripheral organs.
  • D1 vs. D2 in Primates: While Ple389 is D2-specific in mice, the authors couldn't definitively confirm the D1/D2 ratio in the monkey due to technical limitations in co-staining, though the morphology strongly suggested MSNs.

Summary updated

Abstract

<title>Abstract</title> Compact cell type-specific promoters are important tools for basic and preclinical research and clinical delivery of gene therapy. In this work, we designed novel MiniPromoters to target D1 and D2 type dopaminoceptive medium spiny neurons in the striatum by manually identifying candidate regulatory regions or employing the OnTarget webserver. We then empirically tested the designs in rAAV-PHP.B for specificity and robustness in three systems: intravenous injection in mice, intracerebroventricular injection in mice, and intracerebroventricular injection in non-human primates. Twelve MiniPromoters were designed from eight genes: seven manually and five using OnTarget. When delivered intravenously in mice, three MiniPromoters demonstrated highly selective expression in the striatum, with Ple389 (<italic>ADORA2A</italic>) showing high levels of dopamine D2-receptor cell co-localization. The same three MiniPromoters also displayed enriched expression in the striatum when delivered intracerebroventricularly in mice with high levels of DARPP32 co-localization. Finally, Ple389 (<italic>ADORA2A</italic>) was intracerebroventricularly injected in non-human primates and showed enriched expression in the striatum as in the mouse. Ple389 (<italic>ADORA2A</italic>) demonstrated expression in the medium spiny neurons in all three systems tested and exhibited the highest level of D2-MSNs and DARPP32 co-labeling in mice, demonstrating its potential as a tool for gene therapy approaches for Parkinson and Huntington disease treatment.
BibTeX
@inproceedings{gomes2024new,
  author = {A. Gomes and Terri L. Petkau and Andrea J. Korecki and Oriol Fornés and Adriana Galván and Ge Lu and Austin M. Hill and Siu Ling Lam and Andrew Chi-Chih Yao and Rachelle A. Farkas and Wyeth W. Wasserman and Yoland Smith and Elizabeth M. Simpson and Blair R. Leavitt},
  title = {{New MiniPromoter Ple389 (ADORA2A) Drives Selective Expression in Medium Spiny Neurons in Mice and Non-human Primates}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-79004-y},
}
Figure